FDA Clearance Tracker · P230032-S005
AvertD and AvertD Buccal Sample Collection Kit
Last checked: Nov 20, 2026Latest source record: May 20, 2026 (this decision)Source: openFDAMethods & limitations
Decided
May 20, 2026
Approved
Time to decision
28 days
Received Apr 22, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P230032-S005
- Device name
- AvertD and AvertD Buccal Sample Collection Kit
- Applicant
- AutoGenomics, Inc.
- Applicant location
- Carlsbad, CA
- Received
- Apr 22, 2026
- Decided
- May 20, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P230032
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval of the revised protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P230032.
Source documents
Other decisions for AutoGenomics, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- AvertD and AvertD Buccal Sample Collection KitBreakthroughPMA
P230032 · Decided Dec 19, 2023 · 85 days after receipt
Device type: Opioid use disorder genetic risk variant detection system and collection kit (QZH) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.